ArticleBMC cancer2026
Characterizing the spatiotemporal displacement of fiducial markers for cyberknife radiosurgery in liver cancer and identifying predictive factors.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFiducial markers are essential for accurate image-guided stereotactic body radiotherapy (SBRT) in hepatocellular carcinoma (HCC). However, post-implantation positional variation introduces geometric uncertainty. This study aims to quantify the spatiotemporal observed displacement of fiducial markers in HCC patients treated with CyberKnife SBRT and to identify predictive factors for significant displacement.
methodsWe retrospectively reviewed data from 185 HCC patients who underwent percutaneous implantation of 518 fiducial markers between January 2018 and December 2022. Serial CT scans were acquired at baseline (Day 1) and on days 3, 5, 7, 10, and 14 post-implantation. Fiducial displacement was measured in three dimensions (craniocaudal, anteroposterior, mediolateral) relative to the baseline scan after rigid registration to vertebral bodies. Significant displacement was defined as a 3D vector displacement > 3 mm, encompassing true migration and geometrical uncertainties. To account for data clustering (multiple markers per patient), univariate and multivariable Generalized Estimating Equations (GEE) models were used to identify predictors of significant displacement. Internal validation was performed using bootstrap resampling. Furthermore, a dosimetric analysis was conducted to evaluate the clinical impact of significant marker displacement.
resultsThe mean 3D vector displacement was greatest at Day 3 (2.8 ± 1.5 mm) and progressively decreased, plateauing after Day 7 (Day 7: 1.9 ± 1.1 mm; Day 14: 1.8 ± 1.0 mm; p < 0.001 for trend). The craniocaudal axis exhibited the largest magnitude of displacement. By Day 7, 88.6% of markers achieved stability (displacement ≤ 3 mm). Dosimetric evaluation revealed that simulated displacement > 3 mm significantly degraded target coverage (PTV V100%: 98.5% vs. 92.1%, p < 0.001). Multivariate GEE analysis identified tumor location within 2 cm of the diaphragm (Odds Ratio [OR] = 3.05, 95% CI: 1.75-5.20, p < 0.001) and tumor diameter > 5 cm (OR = 1.98, 95% CI: 1.15-3.30, p = 0.012) as independent predictors for significant fiducialisplacement. The optimism-corrected area under the curve (AUC) for the predictive model was 0.76.
conclusionFiducial markers in HCC patients undergo significant early displacement, primarily within the first week, and stabilize thereafter. Proximity to the diaphragm and larger tumor size are associated with a higher risk of displacement, which can negatively impact delivered dosimetry in simulated scenarios. These findings support a recommended 7-day waiting period between implantation and CT simulation as a reasonable safety guideline and suggest that patients with high-risk features may benefit from extended monitoring or adaptive radiotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.